GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Price-to-Free-Cash-Flow

Benitec Biopharma (Benitec Biopharma) Price-to-Free-Cash-Flow : N/A (As of May. 21, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Price-to-Free-Cash-Flow?

As of today (2024-05-21), Benitec Biopharma's share price is $10.47. Benitec Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.05. Hence, Benitec Biopharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Benitec Biopharma's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, Benitec Biopharma's highest Price-to-Free-Cash-Flow Ratio was 189.67. The lowest was 0.00. And the median was 116.91.

BNTC's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.93
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Benitec Biopharma's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-2.36. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-9.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -20.00% per year.

During the past 11 years, Benitec Biopharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 50.70% per year. The lowest was -20.00% per year. And the median was 26.65% per year.


Benitec Biopharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Benitec Biopharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Price-to-Free-Cash-Flow Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.18 - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Benitec Biopharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Benitec Biopharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Price-to-Free-Cash-Flow falls into.



Benitec Biopharma Price-to-Free-Cash-Flow Calculation

Benitec Biopharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=10.47/-9.051
=N/A

Benitec Biopharma's Share Price of today is $10.47.
Benitec Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Benitec Biopharma  (NAS:BNTC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Benitec Biopharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000